Skip to main content
SpringerLink
Log in

Inpatient Prevalence, Expenditures, and Comorbidities of Sarcoidosis: Nationwide Inpatient Sample 2013–2014

  • INTERSTITIAL LUNG DISEASE
  • Published:
Lung Aims and scope Submit manuscript

Abstract

Purpose

To investigate inpatient prevalence, expenditures, and comorbidities of hospitalized patients with sarcoidosis in the USA.

Methods

Patients with sarcoidosis were identified within the Nationwide Inpatient Sample (NIS) database for the years 2013 and 2014 using the respective ICD-9 diagnostic code. Data on patient and hospital characteristics, comorbidities, total hospital costs, and total hospitalization charges were collected. A propensity-matched cohort of patients without sarcoidosis from the same database was created and used as comparators for the analysis of comorbidities.

Results

A cohort of 78,055 patients with sarcoidosis was identified within the database, corresponding to an inpatient prevalence of 2.21 cases per 1000 admissions. Analysis of comorbidities found that patients with sarcoidosis had significantly higher odds of atrial fibrillation [adjusted odds ratio (aOR): 1.41, 95% CI 1.13–1.76, p < 0.01], conduction abnormalities [aOR: 2.04, 95% CI 1.45–2.89, p < 0.01], aortic valvulopathy [aOR: 1.78, 95% CI 1.30–2.44, p < 0.01], congestive heart failure [aOR: 1.23, 95% CI 1.04–1.45, p = 0.02], cardiomyopathy [aOR: 1.25, 95% CI 1.08–1.44, p < 0.01], deep venous thrombosis (aOR: 1.58, p < 0.01), pulmonary embolism (aOR: 1.70, p < 0.01), and osteoporosis (aOR: 1.81, p < 0.01), compared with propensity-matched patients without sarcoidosis. After adjusting for confounders, patients with sarcoidosis displayed a mean additional $1,250 (p = 0.24) in total hospital costs and a mean additional $27,205 (p < 0.01) in total hospitalization charges when compared to hospitalized patients without sarcoidosis.

Conclusions

The inpatient prevalence of sarcoidosis was relatively high compared with its overall incidence. Hospitalization of patients with sarcoidosis was associated with a significantly higher total hospitalization charges compared to hospitalized patients without sarcoidosis. Patients with sarcoidosis have a higher risk of several cardiac comorbidities.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Judson MA, Boan AD, Lackland DT (2012) The clinical course of sarcoidosis: presentation, diagnosis, and treatment in a large white and black cohort in the United States. Sarcoidosis Vasc Diffuse Lung Dis 29:119–127

    CAS  PubMed  Google Scholar 

  2. Israel-Biet D, Valeyre D (2013) Diagnosis of pulmonary sarcoidosis. Curr Opin Pulm Med 19:510–515

    Article  CAS  PubMed  Google Scholar 

  3. Mirsaedi M, Machado RF, Schraufnagel D et al (2015) Racial difference in sarcoidosis mortality in the United States. Chest 147:438–449

    Article  Google Scholar 

  4. Rybicki BA, Major M, Popovich J Jr et al (1997) Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol 145:234–241

    Article  CAS  PubMed  Google Scholar 

  5. Brito-Zeron P, Sellares J, Bosch X et al (2016) Epidemiologic patterns of disease expression in sarcoidosis: age, gender and ethnicity-related differences. Clin Exp Rheumatol 34:380–388

    PubMed  Google Scholar 

  6. Ungprasert P, Carmona EM, Utz JP et al (2016) Epidemiology of sarcoidosis 1946–2013: a population-based study. Mayo Clin Proc 91:183–188

    Article  Google Scholar 

  7. Gribbin J, Hubbard RB, Le Jeune I et al (2006) Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax 61:980–985

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Arkema EV, Grunewald J, Kullberg S et al (2016) Sarcoidosis incidence and prevalence: a nationwide register-based assessment in Sweden. Eur Respir J 48:1690–1699

    Article  PubMed  Google Scholar 

  9. Morimoto T, Azuma A, Abe S et al (2008) Epidemiology of sarcoidosis in Japan. Eur Respir J 31:372–379

    Article  CAS  PubMed  Google Scholar 

  10. Park JE, Kim YS, Kang MJ et al (2018) Prevalence, incidence and mortality of sarcoidosis in Korea, 2003–2015: a nationwide population-based study. Respir Med 144S:S28–S34

    Article  PubMed  Google Scholar 

  11. Gerke AK, Yang M, Tang F et al (2012) Increased hospitalizations among sarcoidosis patients from 1998 to 2008: a population-based cohort study. BMC Pulm Med 12:19

    Article  PubMed  PubMed Central  Google Scholar 

  12. Foreman MG, Mannino DM, Kamugisha L et al (2006) Hospitalization for patients with sarcoidosis: 1979–2000. Sarcoidosis Vasc Diffuse Lung Dis 23:124–129

    PubMed  Google Scholar 

  13. Pohle S, Baty F, Brutsche M (2016) In-hospital disease burden of sarcoidosis in Switzerland from 2002 to 2012. Plos ONE 11:e0151940

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Gorham ED, Garland CF, Garland FC et al (2004) Trends and occupational associations in incidence of hospitalized pulmonary sarcoidosis and other lung diseases in Navy personnel: a 27-year historical prospective study, 1975–2001. Chest 126:1431–1438

    Article  PubMed  Google Scholar 

  15. Deyo RA, Cherkin DC, Ciol MA (1992) Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45:613–619

    Article  CAS  Google Scholar 

  16. Judson MA, Thompson BW, Rabin DL et al (2003) The diagnostic pathway to sarcoidosis. Chest 123:406–412

    Article  PubMed  Google Scholar 

  17. Zoller B, Li X, Sundquist J et al (2012) Risk of subsequent coronary heart disease in patients hospitalized for immune-mediated diseases: a nationwide follow-up study from Sweden. PloS ONE 7:e33442

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Ungprasert P, Crowson CS, Matteson EL (2017) Risk of cardiovascular disease among patients with sarcoidosis: a population-based retrospective cohort study, 1976–2013. Eur Respir J 49:1601290

    Article  PubMed  PubMed Central  Google Scholar 

  19. Yatsynovich Y, Dittoe N, Petrov M et al (2018) Cardiac sarcoidosis: a review of contemporary challenges in diagnosis and treatment. Am J Med Sci 355:113–125

    Article  PubMed  Google Scholar 

  20. Montecucco F, Mach F (2009) Common inflammatory mediators orchestrate pathophysiological processes in rheumatoid arthritis and atherosclerosis. Rheumatology 48:11–22

    Article  CAS  PubMed  Google Scholar 

  21. Raggi P, Genest J, Giles JT et al (2018) Role of inflammation in the pathogenesis of atherosclerosis and therapeutic interventions. Atherosclerosis 276:98–108

    Article  CAS  PubMed  Google Scholar 

  22. Hansson GK (2005) Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352:1685–1695

    Article  CAS  PubMed  Google Scholar 

  23. Xu J, Lupu F, Esmon CT (2010) Inflammation, innate immunity and blood coagulation. Hamostaseologie 30:8–9

    Article  Google Scholar 

  24. Esmon CT (2005) The interactions between inflammation and coagulation. Br J Haematol 131:417–430

    Article  CAS  PubMed  Google Scholar 

  25. Da Silva JA (2011) Safety of glucocorticoids—clinical trials. Clin Exp Rheumatol 29:S99–S103

    PubMed  Google Scholar 

  26. Tukey MH, Berman JS, Boggs DA et al (2013) Mortality among African American women with sarcoidosis: data from the Black Women’s Health Study. Sarcoidosis Vasc Diffuse Lung Dis 30:128–133

    CAS  PubMed  PubMed Central  Google Scholar 

  27. Ungprasert P, Matteson EL, Crowson CS (2017) Accuracy of diagnostic coding for sarcoidosis in electronic databases: a population-based study. Lung 195:713–715

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Epidemiology Unit, Department of Research and Development, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand

    Patompong Ungprasert

  2. Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Jacksonville, FL, USA

    Karn Wijarnpreecha & Paul T. Kröner

  3. Division of Nephrology, Department of Medicine, University of Mississippi Medical Center, Jackson, MS, USA

    Wisit Cheungpasitporn

  4. Division of Nephrology, Department of Medicine, Mayo Clinic, Rochester, MN, USA

    Charat Thongprayoon

  5. Department of Gastroenterology and Hepatology, University of Nebraska Medical Center, Omaha, NE, USA

    Wuttiporn Manatsathit

Authors
  1. Patompong Ungprasert
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Karn Wijarnpreecha
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Wisit Cheungpasitporn
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Charat Thongprayoon
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Wuttiporn Manatsathit
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Paul T. Kröner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Patompong Ungprasert.

Ethics declarations

Conflict of interest

The authors have no financial or non-financial potential conflicts of interest to declare.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 11 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ungprasert, P., Wijarnpreecha, K., Cheungpasitporn, W. et al. Inpatient Prevalence, Expenditures, and Comorbidities of Sarcoidosis: Nationwide Inpatient Sample 2013–2014. Lung 197, 165–171 (2019). https://doi.org/10.1007/s00408-019-00210-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00408-019-00210-x

Keywords

Search

Navigation